| Autor: |
M., MAGHIBEN, A., DAMODARA VELAYUDHAM, RAO, T. UMAMAHESWARA, SMITHA, M. |
| Předmět: |
|
| Zdroj: |
International Journal of Pharmaceutical Research (09752366); 2020 Supplement2, p3678-3681, 4p |
| Abstrakt: |
Sickle cell disease (SCD) is an hereditary Issue initiated by An abandon in the gene to hemoglobin. Patients might bring you quit offering on that one faulty gene (sickle Mobile trait) or two faulty genes (sickle Mobile disease). and globally affects 1,00,000 people with 3,000 affected new born each year in US. The management of the indications of SCD comprises the usage of folate supplements, hydroxy urea, analgesics and antibiotics. Aim: The goal of the learning is to identify the medication utilization design in the organization of patient role with SCD in a tertiary care hospital. Methods: This is a prospective study carried out in general medicine and pediatrics ward of the hospital from November 2018 to April 2019. The information was collected from the case notes by the specially designed data collection form which comprised the demographic data, related co-morbid circumstances and list of prescribed drugs. Data was analyzed using descriptive analysis. Results: A total of 76 SCD patients with the mean age of 12.6 ± 11.3 years and 52.6 % of the affected roleis male. A entire of 515 drugs were arranged by an average of 6.7 drugs per preparation. Conclusion: High rate of folic acid is seen in the prescription with SCD patients followed by hydroxyurea and other hematinics. Our study recommends that WHO/ National Center for Biotechnology information reference guide to recover the patient excellence of life. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
